PRMT5 and hepatocellular carcinoma: In silico analysis was performed to address this point, with RAN and MAPK3 as the genes that were significantly co-expressed with PRMT5 in HCC patients, the genes that correlated with worse prognosis, and genes that were downregulated upon PRMT5 depletion were shortlisted (Supplementary Figure S2).